Day: May 11, 2021

Strengthening the management team with deep anti-infective commercial expertise across hospital and community settings ahead of anticipated approval of Brexafemme (ibrexafungerp) in June 2021 and H2:2021 launchJERSEY CITY, N.J., May 11, 2021 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the appointment of Christine Coyne as Chief Commercial Officer, effective May 10, 2021. Ms. Coyne will play a significant role in the anticipated U.S. launch and commercialization of Brexafemme, the expected trade name for ibrexafungerp, an oral antifungal product candidate for the treatment of vulvovaginal candidiasis (VVC), also known as vaginal yeast infection. The New Drug Application (NDA)...

This marks Verizon’s largest recruitment in retail in more than 5 years BASKING RIDGE, N.J., May 11, 2021 (GLOBE NEWSWIRE) — With excitement growing around new technologies like 5G, new devices and gaming, along with increasing customer visits to its stores, Verizon is launching its largest recruitment effort in more than five years to handle the demand. Nationwide, the company is adding more than 1,000 retail positions to ensure a consistent customer experience. “This is truly an exciting opportunity for anyone looking to be part of a growing industry, and who has a passion for cutting edge technologies like 5G and gaming, and wants to share that passion with others,” said Sean Lee, Senior Vice President of Consumer Sales for Verizon. “The best part is we have positions open nationwide, so if you’ve always wanted to get in the...

MINNEAPOLIS, MN, May 11, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Mitesco, Inc. (OTCQB: MITI) (“Mitesco” or the “Company”), a leading operator of wellness clinics that combine technology and customized personal care plans, today announced that it will present at the Q2 Virtual Investor Summit, hosted by the Investor Summit Group, on May 17, 2021. Larry Diamond, Chief Executive Officer of Mitesco, is scheduled to participate in one-on-one meetings with investors throughout the event and will host a virtual presentation as follows: Q2 Virtual Investor Summit Date: Monday, May 17, 2021 Time: 1:15 p.m. Eastern time  Webcast: https://zoom.us/webinar/register/WN_0-UZgscGTnWLVnabOvX9kA  Registration is mandatory for conference participation. For more information on the conference, to schedule a 1-on-1, or to register for the event,...

U.S. Patent No. 16/376,944 Strengthens C-Bond’s IP Portfolio and the Position of C-Bond nanoShield in the Windshield Strengthening Market HOUSTON, May 11, 2021 (GLOBE NEWSWIRE) — C-Bond Systems (the “Company” or “C-Bond”) (OTC: CBNT), a nanotechnology solutions company, announced today that it has received a notice of allowance from the U.S. Patent and Trademark Office for its C-Bond nanoShield™ windshield strengthening solution. This Patent No. 16/376,944, titled “Multipurpose Solution for Strengthening and Surface Modification Of Glass Substrates,” is the seminal patent for C-Bond nanoShield. Using its proprietary nanotechnology, C-Bond nanoShield protects and strengthens windshields by permeating the glass surface and repairing the microscopic flaws and defects on the glass that ultimately initiate chipping and cracking. The...

WARREN, N.J., May 11, 2021 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2021. “Bellerophon remains focused on advancing its INOpulse® inhaled nitric oxide therapy in multiple high-value areas of unmet need as expeditiously as possible,” said Fabian Tenenbaum, Chief Executive Officer of Bellerophon. “Enrollment in our ongoing pivotal Phase 3 REBUILD study for fibrotic interstitial lung disease, or fILD, patients at risk of associated pulmonary hypertension continues to advance. We also anticipate top-line results from our Phase 2 dose escalation study of INOpulse in...

Mr. Peters currently serves as EMEA Head of Advancing Black Pathways at JPMorgan Chase. London, ENGLAND, May 11, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Bubblr Inc., (OTC PINK: BBLR), (“Bubblr” or the “Company”), an ethical technology company focused on the development and commercialization of mobile-first technologies, has expanded the expertise of its Advisory Board with the appointment of Mr. Cecil Peters, Executive Director, EMEA Head of Advancing Black Pathways for J.P. Morgan Chase and an advocate for technology innovation and data security. Accomplished at leading large global teams through complex change efforts and managing challenging commercial and regulatory environments, prior to joining JPMorgan Chase he previously served as Program Director for Credit Suisse’s cybersecurity program...

SAN ANTONIO, May 11, 2021 (GLOBE NEWSWIRE) — Digerati Technologies, Inc. (OTCQB: DTGI) (“Digerati” or the “Company”), a provider of cloud services specializing in UCaaS (Unified Communications as a Service) solutions for the small to medium-sized business (“SMB”) market, announced today that Digerati CEO, Arthur L. Smith, will present at the Q2 Investor Summit Virtual Conference on Tuesday, May 18 at 4:15pm EDT. The fully immersive conference features live presentations from CEOs of small and mid-cap companies across multiple industries and one-on-one meetings with qualified investors.  Digerati Technologies Presentation at the Q2 Virtual Investor Summit DATE: Tuesday, May 18, 2021  TIME: 4:15 PM Eastern Daylight Time   REGISTRATION: https://investorsummitgroup.com/register/   The Virtual Investor Summit...

SOUTH JORDAN, Utah, May 11, 2021 (GLOBE NEWSWIRE) — Cricut, Inc. (“Cricut”) (NASDAQ: CRCT), the creative technology company that has brought a connected platform for making to millions of users worldwide, today announced that members of its management team are scheduled to present at upcoming investor conferences. Details for each event are as follows: Morgan Stanley Life After COVID Thematic ConferenceTuesday, May 18, 2021 at 2:15 pm ET Baird Global Consumer, Technology & Services ConferenceWednesday, June 9, 2021 at 2:35 pm ET The presentations will be webcast live on the investor relations section of Cricut’s website at https://investor.cricut.com. Replays of the presentations will be available on the website following the completion of each event. About Cricut Cricut Inc. is a creative technology platform company dedicated...

BEVERLY HILLS, Calif., May 11, 2021 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (Nasdaq:TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced it will report results for the first quarter ended March 31, 2021 after the close of the financial markets on Monday, May 17, 2021 and will hold a conference call at 4:30 p.m. ET that day. To participate in the call by phone, dial (877) 545-0320 and entry code 408875 approximately five minutes prior to the scheduled start time. International callers please dial (973) 528-0016 and use entry code 408875. To access the live webcast or view the press release, please visit the Investor Relations section of the TOMI website at:http://investor.tomimist.com/TOMZ/webcasts_and_events/2145 A...

SAN FRANCISCO and TORONTO, May 11, 2021 (GLOBE NEWSWIRE) — Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE (TSXV): CLAS and OTC: KALTF) (the “Company” or “Claritas”) today issued the following letter to shareholders from Robert Farrell, the Company’s President and CEO. Dear Fellow Shareholders, Claritas is well on its way to becoming the industry leader in nitric oxide therapeutics. Nitric oxide is one of the most promising molecules in medicine, however, for reasons I will discuss below, its full potential has never been realized. Our drug, R-107, holds the key to unlocking the full potential of nitric oxide, and I, believe R-107 is the only drug in development that is capable of doing this. R-107, is a patented nitric oxide-releasing compound. The challenge for any biotech company is to demonstrate that its products are...